0001999480-26-000002
SEC filingAlto Neuroscience, Inc. (ANRO), a clinical-stage biopharmaceutical company, reported a net loss of $63.2 million for FY 2025, widening slightly by 3% from $61.4 million in FY 2024, driven by higher other expenses offsetting reduced operating costs. Total operating expenses decreased 3% YoY to $66.4 million, with R&D at $45.6 million (down 3% from $47.0 million) and G&A at $20.7 million (down 4% from $21.6 million). Loss from operations improved to -$66.4 million from -$68.6 million. No revenue was generated, consistent with its pre-commercial stage focused on psychiatry pipeline including ALTO-100, ALTO-300, and others. Cash burn from operations was $51.8 million, offset by $60.1 million in financing inflows, primarily $50.0 million from private placement of common stock and pre-funded warrants, plus term loan proceeds. Ending cash and equivalents stood at $176.5 million, with total liquidity of $177.0 million including restricted cash, supporting operations for at least 12 months. Balance sheet remains solid with $184.7 million total assets and $151.1 million equity. Forward-looking, the company anticipates increasing losses as it advances clinical trials but believes current cash funds needs through mid-2026, though additional financing will be required for full development.
Alto Neuroscience reported FY 2025 net loss of $63.2 million, a 3% increase from $61.4 million in 2024, primarily due to $0.7 million loss on debt extinguishment and higher interest expense, partially offset by improved operating results. Loss from operations narrowed to $66.4 million from $68.6 million, reflecting 3% lower R&D ($45.6 million vs. $47.0 million) and 4% lower G&A ($20.7 million vs. $21.6 million). EPS improved to -$2.19 basic and diluted from -$2.50, on weighted average shares of 28.9 million (up from 24.6 million). Comprehensive loss was $63.1 million. Cash position strengthened to $176.5 million, up from prior periods, via financing activities.
As a clinical-stage biopharmaceutical company with no approved products, Alto generated no revenue in FY 2025 or 2024. Expenses are directed toward pipeline advancement, with R&D comprising 69% of operating expenses ($45.6 million), focused on ALTO-100, ALTO-300, ALTO-101, ALTO-203, and ALTO-207. Direct external program costs included $5.9 million for ALTO-100, $4.5 million for ALTO-300, $5.0 million for ALTO-101, $1.6 million for ALTO-203, and $1.6 million for ALTO-207. The company operates as a single reportable segment.
Pre-revenue status precludes gross or operating margins. Operating loss margin is effectively -100% of expenses. Cost structure showed efficiency gains, with total op ex down 3% YoY despite pipeline progress. Stock-based compensation rose to $8.1 million from $7.6 million, representing 12% of op ex. Non-cash items like depreciation ($0.7 million) and lease expense ($0.8 million) supported ongoing burn management.
Net cash used in operations was $51.8 million, adjusted from net loss by $8.1 million stock comp, $0.7 million depreciation, and working capital changes. Investing used $24K on capex. Financing provided $60.1 million, including $50.0 million private placement net proceeds, $19.7 million term loan, offset by $10.2 million repayment. Net cash increase $8.3 million; ending cash, eq, restricted $177.0 million. Balance sheet: assets $184.7 million (cash 96%), liabilities $33.5 million (term loan $16.8 million total), equity $151.1 million. Accumulated deficit -$201.6 million.
Management estimates current cash funds operations and capex for at least 12 months from filing (March 2026). Substantial additional financing needed for clinical development, regulatory approvals, and commercialization of pipeline. Risks include trial delays, funding needs amid volatility, milestone payments under licenses (e.g., up to $71.5M to Chase), and ongoing litigation. Strategic priorities: advance Phase 2/3 trials for ALTO-100 in bipolar depression, initiate FDA discussions on companion diagnostics.